Vilma Dembitz

3.1k total citations
21 papers, 285 citations indexed

About

Vilma Dembitz is a scholar working on Molecular Biology, Hematology and Cancer Research. According to data from OpenAlex, Vilma Dembitz has authored 21 papers receiving a total of 285 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 14 papers in Hematology and 4 papers in Cancer Research. Recurrent topics in Vilma Dembitz's work include Acute Myeloid Leukemia Research (14 papers), Retinoids in leukemia and cellular processes (6 papers) and Histone Deacetylase Inhibitors Research (5 papers). Vilma Dembitz is often cited by papers focused on Acute Myeloid Leukemia Research (14 papers), Retinoids in leukemia and cellular processes (6 papers) and Histone Deacetylase Inhibitors Research (5 papers). Vilma Dembitz collaborates with scholars based in Croatia, United States and United Kingdom. Vilma Dembitz's co-authors include Dora Višnjić, Hrvoje Lalić, Hrvoje Banfíƈ, Antonio Bedalov, Ivan Kodvanj, Julian A. Simon, Taghi Manshouri, Sherry Pierce, Uri Rozovski and Josip Batinić and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Blood.

In The Last Decade

Vilma Dembitz

21 papers receiving 283 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vilma Dembitz Croatia 10 193 93 47 46 38 21 285
Hrvoje Lalić Croatia 10 153 0.8× 51 0.5× 14 0.3× 53 1.2× 42 1.1× 21 315
Sarah Middleton United States 7 133 0.7× 87 0.9× 10 0.2× 22 0.5× 25 0.7× 9 292
Liling Delila Taiwan 10 130 0.7× 28 0.3× 17 0.4× 12 0.3× 26 0.7× 14 232
Rujiang Zhou China 9 171 0.9× 25 0.3× 20 0.4× 27 0.6× 40 1.1× 16 300
Sonia Poirault‐Chassac France 10 102 0.5× 135 1.5× 49 1.0× 7 0.2× 19 0.5× 17 300
Kimihiko Banno Japan 9 182 0.9× 45 0.5× 25 0.5× 7 0.2× 15 0.4× 12 272
Vamsee D. Myneni Canada 10 64 0.3× 60 0.6× 39 0.8× 44 1.0× 14 0.4× 15 307
Carmen E. Macsai Australia 6 194 1.0× 18 0.2× 37 0.8× 37 0.8× 26 0.7× 7 353
Allison J. Li United States 6 109 0.6× 124 1.3× 49 1.0× 35 0.8× 11 0.3× 7 239
K. Coeleveld Netherlands 12 70 0.4× 142 1.5× 84 1.8× 15 0.3× 21 0.6× 30 374

Countries citing papers authored by Vilma Dembitz

Since Specialization
Citations

This map shows the geographic impact of Vilma Dembitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vilma Dembitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vilma Dembitz more than expected).

Fields of papers citing papers by Vilma Dembitz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vilma Dembitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vilma Dembitz. The network helps show where Vilma Dembitz may publish in the future.

Co-authorship network of co-authors of Vilma Dembitz

This figure shows the co-authorship network connecting the top 25 collaborators of Vilma Dembitz. A scholar is included among the top collaborators of Vilma Dembitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vilma Dembitz. Vilma Dembitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dembitz, Vilma, et al.. (2025). Targeting lipid metabolism in acute myeloid leukemia: biological insights and therapeutic opportunities. Leukemia. 39(8). 1814–1823. 1 indexed citations
2.
Lalić, Hrvoje, Vilma Dembitz, Josip Batinić, et al.. (2024). Bone marrow stromal cells enhance differentiation of acute myeloid leukemia induced by pyrimidine synthesis inhibitors. American Journal of Physiology-Cell Physiology. 327(5). C1202–C1218. 1 indexed citations
3.
Dembitz, Vilma, et al.. (2024). Immunodeficient NBSGW mouse strain allows chemotherapy modeling in AML patient‐derived xenografts. HemaSphere. 8(1). e28–e28. 2 indexed citations
4.
Lalić, Hrvoje, et al.. (2023). Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia. Frontiers in Pharmacology. 14. 1258151–1258151. 2 indexed citations
5.
Giotopoulos, George, Pedro Madrigal, Céline Philippe, et al.. (2023). Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death. Nature Communications. 14(1). 2132–2132. 14 indexed citations
6.
Lalić, Hrvoje, Vilma Dembitz, Josip Batinić, et al.. (2022). Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis. Scientific Reports. 12(1). 11344–11344. 8 indexed citations
7.
Višnjić, Dora, et al.. (2021). AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review. Cells. 10(5). 1095–1095. 93 indexed citations
8.
Dembitz, Vilma, Hrvoje Lalić, Josip Batinić, et al.. (2021). All-trans retinoic acid induces differentiation in primary acute myeloid leukemia blasts carrying an inversion of chromosome 16. International Journal of Hematology. 115(1). 43–53. 6 indexed citations
9.
Giotopoulos, George, Pedro Madrigal, Konstantinos Tzelepis, et al.. (2021). Mannose Metabolism Is a Metabolic Vulnerability Unveiled By Standard and Novel Therapies in Acute Myeloid Leukemia. Blood. 138(Supplement 1). 508–508. 1 indexed citations
10.
Dembitz, Vilma & Paolo Gallipoli. (2021). The Role of Metabolism in the Development of Personalized Therapies in Acute Myeloid Leukemia. Frontiers in Oncology. 11. 665291–665291. 3 indexed citations
11.
Dembitz, Vilma, Hrvoje Lalić, Ivan Kodvanj, et al.. (2020). 5-aminoimidazole-4-carboxamide ribonucleoside induces differentiation in a subset of primary acute myeloid leukemia blasts. BMC Cancer. 20(1). 1090–1090. 6 indexed citations
12.
Dembitz, Vilma, et al.. (2019). The ribonucleoside AICAr induces differentiation of myeloid leukemia by activating the ATR/Chk1 via pyrimidine depletion. Journal of Biological Chemistry. 294(42). 15257–15270. 18 indexed citations
13.
Višnjić, Dora, Vilma Dembitz, & Hrvoje Lalić. (2018). The Role of AMPK/mTOR Modulators in the Therapy of Acute Myeloid Leukemia. Current Medicinal Chemistry. 26(12). 2208–2229. 21 indexed citations
14.
Dembitz, Vilma, Hrvoje Lalić, & Dora Višnjić. (2017). 5-Aminoimidazole-4-carboxamide ribonucleoside-induced autophagy flux during differentiation of monocytic leukemia cells. Cell Death Discovery. 3(1). 17066–17066. 16 indexed citations
15.
Rozovski, Uri, Srđan Verstovšek, Taghi Manshouri, et al.. (2016). An accurate, simple prognostic model consisting of age, JAK2 , CALR , and MPL mutation status for patients with primary myelofibrosis. Haematologica. 102(1). 79–84. 29 indexed citations
16.
Banfíƈ, Hrvoje, et al.. (2015). Inositol pyrophosphates modulate cell cycle independently of alteration in telomere length. Advances in Biological Regulation. 60. 22–28. 12 indexed citations
17.
Dembitz, Vilma, et al.. (2015). The mechanism of synergistic effects of arsenic trioxide and rapamycin in acute myeloid leukemia cell lines lacking typical t(15;17) translocation. International Journal of Hematology. 102(1). 12–24. 9 indexed citations
18.
Višnjić, Dora, Hrvoje Lalić, Vilma Dembitz, & Hrvoje Banfíƈ. (2014). Metabolism and differentiation. Periodicum Biologorum. 116(1). 37–43. 14 indexed citations
19.
Lalić, Hrvoje, et al.. (2013). 5-Aminoimidazole-4-carboxamide ribonucleoside induces differentiation of acute myeloid leukemia cells. Leukemia & lymphoma. 55(10). 2375–2383. 15 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hrvoje Lalić Breakdown of academic impact, for papers by Sarah Middleton Breakdown of academic impact, for papers by Liling Delila Breakdown of academic impact, for papers by Rujiang Zhou Breakdown of academic impact, for papers by Sonia Poirault‐Chassac Breakdown of academic impact, for papers by Kimihiko Banno Breakdown of academic impact, for papers by Vamsee D. Myneni Breakdown of academic impact, for papers by Carmen E. Macsai Breakdown of academic impact, for papers by Allison J. Li Breakdown of academic impact, for papers by K. Coeleveld
Rankless by CCL
2026